GrayMatters Health (GMH) develops digital self-neuromodulation therapeutics for mental disorders to help patients regain agency over their emotion regulation.

GMH offers Prism, a noninvasive adjunct therapeutic that utilizes novel neuroscience-based and brain-mechanism-specific biomarkers.

The company's first product candidate, Prism for post-traumatic stress disorder (PTSD), is undergoing clinical investigation in five sites across the United States and Israel, to demonstrate its efficacy and safety as an adjunct to standard PTSD treatments.

Our first product, Prism for PTSD, was cleared by FDA in March 2023.The novel technology was developed by Professor Talma Hendler and her team at Tel Aviv Sourasky Medical Center and Tel Aviv University.